Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $2,076,800.00 in Stock
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the business's stock in a transaction dated Thursday, January 19th. The stock was sold at an average p
United Therapeutics Co. (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" From Brokerages
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) has received a consensus rating of "Moderate Buy" from the fourteen brokerages that are covering the firm, Marketbeat reports. Two research analyst
Financial Gravity Asset Management Inc. Has $2.34 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)
Financial Gravity Asset Management Inc. lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 146.0% in the third quarter, HoldingsChannel reports. The institutional
Martine A. Rothblatt Sells 8,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an
Cwm LLC Has $66,000 Stake in United Therapeutics Co. (NASDAQ:UTHR)
Cwm LLC grew its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 132.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and
United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $2,092,160.00 in Stock
United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the firm's stock in a transaction on Friday, January 13th. The shares were sold at an average price of
Seizert Capital Partners LLC Has $7.16 Million Position in United Therapeutics Co. (NASDAQ:UTHR)
Seizert Capital Partners LLC lowered its position in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 1.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Ex
Tekla Capital Management LLC Increases Position in United Therapeutics Co. (NASDAQ:UTHR)
Tekla Capital Management LLC lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 62.6% during the third quarter, Holdings Channel reports. The fund owned 117,377 s
United Therapeutics Co. (NASDAQ:UTHR) Stock Position Lessened by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 36.9% in the 3rd quarter, according to the company in its most recent discl
Argus Raises United Therapeutics (NASDAQ:UTHR) Price Target to $300.00
United Therapeutics (NASDAQ:UTHR – Get Rating) had its target price hoisted by Argus from $250.00 to $300.00 in a research note published on Wednesday morning, Benzinga reports. They currently have a
Loading...
No Stock Yet